SAN DIEGO, March 23, 2017 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ:RTRX) today announced the appointment of
John A. Orwin to the Company’s Board of Directors, effective immediately. Mr. Orwin currently serves as chief executive officer of
Relypsa, Inc., a biopharmaceutical company focused on developing treatments for patients with conditions that are often overlooked
and undertreated.
“John’s operational and commercial expertise strengthens our Board and will be invaluable to Retrophin as we
advance our late-stage pipeline towards commercialization while maximizing the potential of our approved therapies,” said Stephen
Aselage, chief executive officer of Retrophin. “We are very pleased John is joining us at this exciting time and look forward to
his leadership.”
Mr. Orwin is a biopharmaceutical industry veteran with more than 25 years of experience. He has served as chief
executive officer of Relypsa since 2013. Previously, Mr. Orwin was chief executive officer and a director of Affymax. Before
joining Affymax, Mr. Orwin held leadership positions in marketing, sales, and operations at Genentech, Johnson and Johnson, Alza
Pharmaceuticals, Sangstat Medical Corporation, Rhone-Poulenc Rorer, and Schering-Plough. Mr. Orwin currently serves as a director
of Seattle Genetics and Array BioPharma. Mr. Orwin earned a bachelor’s degree from Rutgers University and master’s degree in
business administration from New York University.
About Retrophin
Retrophin is a fully integrated biopharmaceutical company dedicated to delivering life-changing therapies to people
living with rare diseases who have few, if any, treatment options. The Company's approach centers on its pipeline featuring
late-stage candidates targeting rare diseases with significant unmet medical needs, including sparsentan for focal segmental
glomerulosclerosis (FSGS), a disorder characterized by progressive scarring of the kidney often leading to end-stage renal disease,
and RE-024 for pantothenate kinase-associated neurodegeneration (PKAN), a life-threatening neurological disorder that typically
begins in early childhood. Research exploring the potential of early-stage assets in several rare diseases is also underway.
Retrophin's R&D efforts are supported by revenues from the Company's commercial products, Thiola®, Cholbam®, and Chenodal®.
Retrophin.com
Forward-Looking Statements
This press release contains "forward-looking statements" as that term is defined in the Private Securities
Litigation Reform Act of 1995, regarding the research, development and commercialization of pharmaceutical products. Without
limiting the foregoing, these statements are often identified by the words "may", "might", "believes", "thinks", "anticipates",
"plans", "expects", "intends" or similar expressions. In addition, expressions of our strategies, intentions or plans are also
forward-looking statements. Such forward-looking statements are based on current expectations and involve inherent risks and
uncertainties, including factors that could delay, divert or change any of them, and could cause actual outcomes and results to
differ materially from current expectations. No forward-looking statement can be guaranteed. Among the factors that could cause
actual results to differ materially from those indicated in the forward-looking statements are risks and uncertainties associated
with the Company's business and finances in general, success of its commercial products as well as risks and uncertainties
associated with the Company's pre-clinical and clinical stage pipeline. You are cautioned not to place undue reliance on these
forward-looking statements as there are important factors that could cause actual results to differ materially from those in
forward-looking statements, many of which are beyond our control. The Company undertakes no obligation to publicly update
forward-looking statement, whether as a result of new information, future events, or otherwise. Investors are referred to the full
discussion of risks and uncertainties as included in the Company's most recent 10-K and other filings with the Securities and
Exchange Commission.
Contact: Chris Cline, CFA Senior Director, Investor Relations 646-564-3680 IR@retrophin.com
